Healthcare AINVIDIA BioNeMo Locks In as Pharma AI Standard; Novo Nordisk Surges 24.9% on AI Licensing DealSalvado•Jun 27, 2026
Healthcare AINovo Nordisk Outsources Parkinson's Program as NVIDIA's BioNeMo Turns Drug Discovery Into InfrastructureSalvado•Jun 25, 2026
Healthcare AINVIDIA's BioNeMo Anchors Drug Discovery Stack as Pharma Outsources R&D to AI PlatformsSalvado•Jun 19, 2026
Healthcare AINVIDIA BioNeMo Becomes Pharma's AI Backbone as Novo Nordisk Outsources Parkinson's R&DSalvado•Jun 9, 2026
Biotech AINVIDIA BioNeMo Locks In Pharma Partnerships as Novo Nordisk Outsources Parkinson's Therapy to AI SpecialistSalvado•Jun 5, 2026
Healthcare AINVIDIA BioNeMo Locks In Enterprise Drug Discovery as Pharma Shifts R&D to AI InfrastructureSalvado•Jun 1, 2026
Healthcare AINVIDIA's BioNeMo Locks In Pharma Giants as AI Drug Discovery Becomes Table StakesSalvado•May 31, 2026
Healthcare AINVIDIA's BioNeMo Locks In Eli Lilly and Thermo Fisher as Five Rivals Race for the Drug Discovery StackSalvado•May 27, 2026
Healthcare AINVIDIA's BioNeMo Becomes Drug Discovery's Default AI Backbone as Big Pharma Outsources Frontier BiologySalvado•May 21, 2026
Healthcare AINVIDIA's BioNeMo Emerges as Core Infrastructure Layer as Pharma Rebuilds R&D Around AI PlatformsSalvado•May 18, 2026
Healthcare AINVIDIA's BioNeMo Becomes Drug Discovery Infrastructure as Eli Lilly, Thermo Fisher Sign OnSalvado•May 16, 2026
Healthcare AINovo Nordisk Stock Jumps 24.9% as Pharma Pivots from Wet Labs to AI InfrastructureSalvado•May 13, 2026
